Home/Pipeline/WS016

WS016

Diabetic Kidney Disease (DKD)

Phase 3Active (FDA-approved to proceed directly to Phase 3 in US)

Key Facts

Indication

Diabetic Kidney Disease (DKD)

Phase

Phase 3

Status

Active (FDA-approved to proceed directly to Phase 3 in US)

Company

Waterstone Pharmaceuticals

About Waterstone Pharmaceuticals

A China-based biotech developing polymer-based therapeutics for metabolic diseases like diabetic kidney disease, with a lead asset advancing to Phase 3 in the US.

View full company profile

Therapeutic Areas

Metabolic Disease Nephrology

Other Diabetic Kidney Disease (DKD) Drugs

Drug	Company	Phase	Status
SR1375	SIMR (Australia) Biotech	Phase not specified (Novel treatment)	Active (Oral presentation delivered)
Vonafexor (EYP001)	ENYO Pharma	Development	Active
ORBCEL™ for Diabetic Kidney Disease (NEPHSTROM Trial)	Orbsen Therapeutics	Phase 2	Active